These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 26277539)
41. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204 [TBL] [Abstract][Full Text] [Related]
42. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer. Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708 [TBL] [Abstract][Full Text] [Related]
43. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Huang TS; Myklebust LM; Kjarland E; Gjertsen BT; Pendino F; Bruserud Ø; Døskeland SO; Lillehaug JR Mol Cancer; 2007 Apr; 6():31. PubMed ID: 17451600 [TBL] [Abstract][Full Text] [Related]
44. Cancer-selective cytotoxic Ca2+ overload in acute myeloid leukemia cells and attenuation of disease progression in mice by synergistically acting polyphenols curcumin and carnosic acid. Pesakhov S; Nachliely M; Barvish Z; Aqaqe N; Schwartzman B; Voronov E; Sharoni Y; Studzinski GP; Fishman D; Danilenko M Oncotarget; 2016 May; 7(22):31847-61. PubMed ID: 26870993 [TBL] [Abstract][Full Text] [Related]
45. Drug resistance: still a daunting challenge to the successful treatment of AML. Shaffer BC; Gillet JP; Patel C; Baer MR; Bates SE; Gottesman MM Drug Resist Updat; 2012; 15(1-2):62-9. PubMed ID: 22409994 [TBL] [Abstract][Full Text] [Related]
46. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis. Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972 [TBL] [Abstract][Full Text] [Related]
47. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage. Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238 [TBL] [Abstract][Full Text] [Related]
48. Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity. Wozniak KM; Vornov JJ; Wu Y; Nomoto K; Littlefield BA; DesJardins C; Yu Y; Lai G; Reyderman L; Wong N; Slusher BS Cancer Res; 2016 Jun; 76(11):3332-9. PubMed ID: 27197173 [TBL] [Abstract][Full Text] [Related]
49. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia. Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890 [TBL] [Abstract][Full Text] [Related]
50. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells. Stuhldreier F; Kassel S; Schumacher L; Wesselborg S; Proksch P; Fritz G Cancer Lett; 2015 May; 361(1):39-48. PubMed ID: 25697484 [TBL] [Abstract][Full Text] [Related]
51. Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. Zhang Q; Lu Y; Ding Y; Zhai J; Ji Q; Ma W; Yang M; Fan H; Long J; Tong Z; Shi Y; Jia Y; Han B; Zhang W; Qiu C; Ma X; Li Q; Shi Q; Zhang H; Li D; Zhang J; Lin J; Li LY; Gao Y; Chen Y J Med Chem; 2012 Oct; 55(20):8757-69. PubMed ID: 22985027 [TBL] [Abstract][Full Text] [Related]
52. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076 [TBL] [Abstract][Full Text] [Related]
53. Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. Mizuuchi H; Suda K; Sato K; Tomida S; Fujita Y; Kobayashi Y; Maehara Y; Sekido Y; Nishio K; Mitsudomi T PLoS One; 2015; 10(4):e0123901. PubMed ID: 25875914 [TBL] [Abstract][Full Text] [Related]
54. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. Bosman MC; Schuringa JJ; Quax WJ; Vellenga E Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210 [TBL] [Abstract][Full Text] [Related]
55. Heme oxygenase-1 plays a crucial role in chemoresistance in acute myeloid leukemia. Zhe N; Wang J; Chen S; Lin X; Chai Q; Zhang Y; Zhao J; Fang Q Hematology; 2015 Aug; 20(7):384-91. PubMed ID: 26218201 [TBL] [Abstract][Full Text] [Related]
56. c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Lagadinou ED; Ziros PG; Tsopra OA; Dimas K; Kokkinou D; Thanopoulou E; Karakantza M; Pantazis P; Spyridonidis A; Zoumbos NC Leukemia; 2008 Oct; 22(10):1899-908. PubMed ID: 18650843 [TBL] [Abstract][Full Text] [Related]
57. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance. Li L; Huang X; Huang R; Gou S; Wang Z; Wang H Eur J Med Chem; 2018 Aug; 156():666-679. PubMed ID: 30031977 [TBL] [Abstract][Full Text] [Related]
58. Clustering of endocytic organelles in parental and drug-resistant myeloid leukaemia cell lines lacking centrosomally organised microtubule arrays. Jin J; Pastrello D; Penning NA; Jones AT Int J Biochem Cell Biol; 2008; 40(10):2240-52. PubMed ID: 18439867 [TBL] [Abstract][Full Text] [Related]
59. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834 [TBL] [Abstract][Full Text] [Related]
60. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Wong TN; Ramsingh G; Young AL; Miller CA; Touma W; Welch JS; Lamprecht TL; Shen D; Hundal J; Fulton RS; Heath S; Baty JD; Klco JM; Ding L; Mardis ER; Westervelt P; DiPersio JF; Walter MJ; Graubert TA; Ley TJ; Druley T; Link DC; Wilson RK Nature; 2015 Feb; 518(7540):552-555. PubMed ID: 25487151 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]